Lysosome associated protein transmembrane 4 beta (LAPTM4b) is also a cancer-associated gene and the amplification of LAPTM4b was found to be a biomarker indicating a treatment resistance to doxorubicin and an increased risk of recurrence of breast cancer. This evidence concerns the gene LAPTM4B and breast carcinoma.